Literature DB >> 17911483

Self-reactivity in the dimeric intravenous immunoglobulin fraction.

Alexander Schaub1, Sandra Wymann, Manfred Heller, Marco Ghielmetti, Zsuzsanne Beleznay, Beda M Stadler, Reinhard Bolli, Sylvia Miescher.   

Abstract

Therapeutic intravenous immunoglobulin (IVIg) preparations contain antibodies reflecting the cumulative antigen experience of the donor population. IVIg contains variable amounts of monomeric and dimeric IgG, but there is little information available on their comparative antibody specificities. We have isolated highly purified fractions of monomeric and dimeric IgG by size-exclusion chromatography. Following treatment of all fractions at pH4, analyses by immunodot and immunocytology on human cell lines showed a preferential recognition of autoantigens in the dimeric IgG fraction. Investigation of the HEp-2 cytoplasmic proteome by 2D-PAGE, Western blot, and subsequent identification of IVIg reactive spots by mass spectrometry (LC-MS/MS) showed that IVIg recognized only a restricted set of the total proteins. Similar experiments showed that more antigens were recognized by the dimeric IgG fraction, especially when the dissociated dimer fraction was used, as compared to its monomeric counterpart. These observations are consistent with idiotype-anti-idiotype masking of auto-specific Abs in the dimeric fraction of IVIg.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17911483     DOI: 10.1196/annals.1423.071

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

1.  Anti-idiotypic Fab Fragments Image a Conserved N-terminal Epitope Patch of Grass Pollen Allergen Phl p 1.

Authors:  Anna Lukschal; Jan Fuhrmann; Juryj Sobanov; Dirk Neumann; Julia Wallmann; Regina Knittelfelder; Wolfgang Hemmer; Otto Scheiner; Monique Vogel; Beda M Stadler; Erika Jensen-Jarolim; Krisztina Szalai
Journal:  Open Allergy J       Date:  2011-05-23

2.  Intravenous immunoglobulins. Current understanding and future directions.

Authors:  S Jolles; S V Kaveri; J Orange
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

Review 3.  Intravenous immunoglobulins--understanding properties and mechanisms.

Authors:  A Durandy; S V Kaveri; T W Kuijpers; M Basta; S Miescher; J V Ravetch; R Rieben
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

4.  IVIG regulates the survival of human but not mouse neutrophils.

Authors:  Christoph Schneider; Simone Wicki; Stefanie Graeter; Tankica M Timcheva; Christian W Keller; Isaak Quast; Danila Leontyev; Iglika K Djoumerska-Alexieva; Fabian Käsermann; Stephan M Jakob; Petya A Dimitrova; Donald R Branch; Richard D Cummings; Jan D Lünemann; Thomas Kaufmann; Hans-Uwe Simon; Stephan von Gunten
Journal:  Sci Rep       Date:  2017-05-02       Impact factor: 4.379

Review 5.  Phenotyping of Adaptive Immune Responses in Inflammatory Diseases.

Authors:  Jens Y Humrich; Joana P Bernardes; Ralf J Ludwig; David Klatzmann; Alexander Scheffold
Journal:  Front Immunol       Date:  2020-11-25       Impact factor: 7.561

6.  Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins.

Authors:  Christian Ritter; Ilja Bobylev; Helmar C Lehmann
Journal:  J Neuroinflammation       Date:  2015-08-14       Impact factor: 8.322

7.  Effect of IVIG Formulation on IgG Binding to Self- and Exo- Antigens In Vitro and In Vivo.

Authors:  Susann Cattepoel; Annette Gaida; Alain Kropf; Marc W Nolte; Reinhard Bolli; Sylvia M Miescher
Journal:  PLoS One       Date:  2016-08-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.